Soybean bowman-birk protease inhibitor (BBI): Identification of the mechanisms of BBI suppressive effect on growth of two adenocarcinoma cell lines: AGS and HT29

Archives of Medical Research

Volumn 45, Issue 6, 2014, Pages 455-461

  Fereidunian, Amirhossein ^a   Sadeghalvad, Mona ^a   Oscoie, Maryam Omidi ^a   Mostafaie, Ali ^a,b  

^a KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Angiogenesis; Bowman Birk protease inhibitor; Matrix metalloproteinase; Purification; Vascular endothelial growth factor

Indexed keywords

BOWMAN BIRK INHIBITOR; GELATINASE A; GELATINASE B; VASCULOTROPIN; TRYPSIN INHIBITOR; TUMOR MARKER; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGS CELL LINE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CELL TYPE; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG PURIFICATION; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME SYNTHESIS; GASTRIC CANCER CELL LINE; HT 29 CELL LINE; HUMAN; HUMAN CELL; ION EXCHANGE CHROMATOGRAPHY; PROTEIN SECRETION; SOYBEAN; STOMACH ADENOCARCINOMA; ZYMOGRAPHY; ADENOCARCINOMA; DRUG EFFECTS; EVALUATION STUDY; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ADENOCARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HT29 CELLS; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; TRYPSIN INHIBITOR, BOWMAN-BIRK SOYBEAN; TRYPSIN INHIBITORS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84908067314     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2014.07.001     Document Type: Article

References (25)

1. Lambert M.P. Epigenetics and cancers, 2nd IARC meeting, Lyon, 6 and 7 December 2007. Mol Oncol 2008, 2:33-40.
2. Kondo Y., Issa J.P. DNA methylation profiling in cancer. Exp Rev Mol Med 2010, 12:e23.
3. Hanahan D., Coussens L.M. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012, 21:309-322.
4. Bhat T.A., Singh R.P. Tumor angiogenesis: a potential target in cancer chemoprevention. Food Chem Toxicol 2008, 46:1334-1345.
5. Bourboulia D., Stetler-Stevenson W.G. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): positive and negative regulator in tumor cell adhesion. Semin Cancer Biol 2010, 20:161-168.
6. Roy R., Zhang B., Moses M.A. Making the cut: protease-mediated regulation of angiogenesis. Exp Cell Res 2006, 312:608-622.
7. Neufeld G., Cohen T., Gengrinovitch S., et al. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999, 13:9-22.
8. Collet G., Skrzypek K., Grillon C., et al. Hypoxia control to normalize pathologic angiogenesis: potential role for endothelial precursor cells and miRNAs regulation. Vascular Pharmacol 2012, 56:252-261.
9. Helfrich I., Schadendorf D. Blood vessel maturation, vascular phenotype and angiogenic potential in malignant melanoma: one step forward for overcoming anti-angiogenic drug resistance?. Mol Oncol 2011, 5:137-149.
10. Kennedy A.R. Chemopreventive agents: protease inhibitors. Pharmacol Ther 1998, 78:167-209.
11. Witschi H., Espiritu I. Development of tobacco smoke-induced lung tumors in mice fed Bowman-Birk protease inhibitor concentrate. Cancer Lett 2002, 183:141-146.
12. Kennedy A.R., Beazer-Barclay Y., Kinzler K.W., et al. Suppression of carcinogenesis in the intestine of min mice by the soybean-derived Bowman-Birk inhibitor. Cancer Res 1996, 56:679-682.
13. Kennedy A.R., Wan X.S. Effects of the Bowman-Birk inhibitor on growth, invasion, and clonogenic survival of human prostate epithelial cells and prostate cancer cells. Prostate 2002, 50:125-133.
14. Kennedy A.R. The evidence for soybean products as cancer preventive agents. J Nutr 1995, 125:733S-743S.
15. Yavelow J., Collins M., Birk Y., et al. Nanomolar concentrations of Bowman-Birk soybean protease inhibitor suppresses x-ray-induced transformation invitro. Proc Nati Acad Sci USA 1985, 82:5395-5399.
16. Laskowski M., Schwert C.W., Takenaka Y. Methods in enzymology. Biochem Biophys Acta 1955, 16:570.
17. Decker T., Lohmann-Matthes M.L. A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J Immunol Methods 1988, 115:61-69.
18. Rechtman M.P., Zhang J., Salamonsen L.A. Effect of inhibition of matrix metalloproteinases on endometrial decidualization and implantation in mated rats. J Reprod Fertil 1999, 117:169-177.
19. Bradford M.M. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
20. Chen Y.W., Huang S.C., Lin-Shiau S.Y., et al. Bowman-Birk protease inhibitor abates proteasome function and suppresses the proliferation of MCF7 breast cancer cells through accumulation of MAP kinase phosphatase-1. Carcinogenesis 2005, 26:1296-1306.
21. Saito T., Sato H., Virgona N., et al. Negative growth control of osteosarcoma cell by Bowman-Birk protease inhibitor from soybean; involvement of connexin43. Cancer Lett 2007, 253:249-257.
22. Billings P.C., St Clair W.H., Maki P.A., et al. Distribution of Bowman Birk protease inhibitor in mice following oral administration. Cancer Lett 1992, 62:191-197.
23. Westermarck J., Kahari V.M. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 1999, 13:781-792.
24. Himelstein B.P., Canete-Soler R., Bernhard E.J., et al. Metalloproteinases in tumor progression: the contribution of MMP-9. Invasion Metastasis 1994-1995, 14:246-258.
25. Sharma S., Ghoddoussi M., Gao P., et al. A quantitative angiogenesis model for efficacy testing of chemopreventive agents. Anticancer Res 2001, 21:3829-3837.